Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q3 2022 · 10-Q
Revenue$29.70M$29.70M+230.9% vs Q3 2021 Net Income$1.62M$1.62MN/M vs Q3 2021 EPS Diluted$0.04$0.04N/M vs Q3 2021 Operating Income$660,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$25,267,000N/M Margins · derivedOperating margin2.2%+132.7 pt vs Q3 2021
Net margin5.4%+134.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end